NewAmsterdam Pharma Company NAMS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$48.44M-22.6% | -$74.92M+18.7% | -$72.01M-333% | -$17.36M+55.5% | -$39.53M+57.8% | ||
| $62K+19.2% | $59K+15.7% | $64K+129% | $45K+137% | $52K+247% | ||
| $18M+18.3% | $14.02M+48.9% | $15.01M+87.7% | $15.18M+83.1% | $15.21M+92.1% | ||
| $10K+102% | -$24K+57.7% | -$396K-598% | -$472K-732% | -$513K-804% | ||
| -$12K— | -$11K— | -$1K— | —— | —— | ||
| -$793K-135% | $5.32M+266% | -$2.27M— | $0+100% | $2.25M+127% | ||
| -$10.33M-109% | $5.32M+122% | —— | —— | -$4.95M-259% | ||
| —— | —— | —— | -$3.03M-33.0% | -$2.98M-113% | ||
| -$30.6M+16.1% | -$40.88M-9.1% | -$32.77M-162% | -$37.67M+30.2% | -$36.47M+33.2% | ||
| $38K+138% | $100K+3,233% | $42K-44.0% | $88K-57.9% | $16K-95.8% | ||
| -$11.51M-503% | -$21.14M+66.0% | $0+100% | -$159.14M-76,042% | $2.86M+842% | ||
| $10.41M+31.5% | $12.5M+885% | $5.62M+9,586% | $3.42M— | $7.92M+1,700% | ||
| $11.07M+69.7% | $13.68M-97.0% | $5.89M+10,059% | $3.43M-26.5% | $6.52M-96.7% | ||
| -$1.33M-135% | $0+100% | $222K-95.1% | $8.83M+1,071% | $3.77M+251% | ||
| -$31.05M-14.6% | -$48.33M-114% | -$24.37M— | -$193.38M— | -$27.09M-119% | ||
| —— | —— | —— | —— | —— | ||
| $10K+102% | -$24K+57.7% | -$396K-598% | -$472K-732% | -$513K-804% | ||
| -$5.94M+66.5% | $15.34M-66.3% | $23.79M+2,990% | -$2.59M— | -$17.75M-146% | ||
| -$1.61M-138% | $0+100% | $218K-95.3% | $8.63M+968% | $4.29M+278% | ||
| -$12K— | -$11K— | -$1K— | —— | —— | ||
| -$10.33M-109% | $5.32M+122% | —— | —— | -$4.95M-259% | ||
| —— | —— | —— | -$3.03M-33.0% | -$2.98M-113% | ||
| -$15.22M+5.1% | $10.06M+15.8% | —— | $21.86M+137% | -$16.03M-1,577% | ||
| -$16K-633% | —— | —— | —— | $3K+200% | ||
| —— | —— | —— | —— | $1.59M+208% | ||
| $651K+256% | $1.18M+247% | $274K— | $1K-100.0% | $183K-97.9% | ||
| -$1.33M-135% | $0+100% | $222K-95.1% | $8.83M+1,071% | $3.77M+251% | ||
| —— | —— | —— | —— | $40.81M— | ||
| —— | —— | —— | —— | —— | ||
| -$30.64M+16.0% | -$40.98M-9.3% | -$32.81M-161% | -$37.76M+30.3% | -$36.48M+33.6% | ||
| -$30.64M+16.0% | -$40.98M-9.3% | -$32.81M-161% | -$37.76M+30.3% | -$36.48M+33.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does NewAmsterdam Pharma Company's cash flow data come from?
- Every line is extracted from NewAmsterdam Pharma Company's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.